Super proud of our trials team today! We have randomised the first patient in the UK to a major phase 3 trial in pancreatic cancer that has the potential to change first line treatment for patients.

Delighted to have the opportunity to present to the NIHR strategy board on Birmingham’s leading pancreatic cancer trial portfolio with infant in tow (inset day equals daddy day care).

I would love to see a real world evidence study of giving mounjaro or ozempic to newly diagnosed type 2 diabetes patients in the nhs. It would be a gamechanger for patients and the nhs.

Thanks Ben, especially with the contributions from you and your lab!

Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms - Nature Communications Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis involving evasion of immune control. Here, the authors perform a comprehensive analysis of single-cell multi-omic data revealing either a m...

Ecstatic to see this out! Important implications for immune targeting in pancreatic cancer. Has been a labour of love! Lots of fantastic collaborators and important new early phase trials being set up!

www.nature.com/articles/s41...

Though I still find it puzzling in norpact trial how 50% of patients couldn’t finish 4 cycles of neoadjuvant folfirinox. Very different to my practice.

Adjuvant Chemotherapy After Resection of Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX This cohort study investigates the association of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative FOLFIRINOX in full or modified dosing with overall survival,...

Important study, this suggests that if give patients 8 cycles of neoadjuvant chemotherapy, no benefit of adjuvant. I’m sure most patients would prefer upfront chemotherapy.

jamanetwork.com/journals/jam...

Also worth seeing in the kras G12D population whether pan-RAs or G12D inhibitors are better for upfront treatment

Is this going to lead to a change in care soon?

Pan-RAS inhibitor RMC-6236 aka Daraxonrasib in patients with RAS-mutant pancreatic adenocarcinoma 🤯🤯🤯 #GI25
dailynews.ascopubs.org/do/pan-ras-i...

Looks like we are on the verge of something quite exciting in pancreatic cancer…

dailynews.ascopubs.org/do/pan-ras-i...

Multianalyte blood-based risk stratification of incidental pancreas lesions Purpose Incidental detection of pancreas lesions (IPLs) is common and creates an opportunity to intercept pancreatic ductal adenocarcinoma (PDAC). However, identifying patients at risk for progression...

Preprint alert! Delighted to be part of this collaboration where we used a new fragmentomic method in a multi-analyte setting to understand which high risk pancreas lesions could become cancer. Potential large benefits for patients.

www.medrxiv.org/content/10.1...

This has been much delayed coming in. Still no coherent obesity plan for the UK. Biggest reason for the decline of healthcare of people and nhs. @rthonwesstreeting.bsky.social need to be more ambitious with obesity including earlier implementation of GLP-1 agonists and food reform.

Afghanistan: Women suspended from midwife and nurse training - BBC News Women at training colleges across the country were told they are not allowed to return to class.

I am genuinely perplexed on why the world seems to be deafeningly silent on women’s rights in Afganhistan. Where are the protests and the outrage?

www.bbc.com/news/article...

In the University of Birmingham alumni magazine, it was announced that a former patient of mine and their family had kindly philanthropically raised funds for me and colleagues to have a student to study an understudied part of the immune system in pancreatic cancer.
www.oldjoe.co.uk/article/reas...

🤓 Our team enjoyed fantastic presentations by Adam Cunningham, Arzoo Patel with Palak Trivedi and Shivan Sivakumar on immunity to Salmonella, the gut microbiome in autoimmune liver diseases and pancreatic cancer therapies.

It feels we are closer than ever to getting a new meaningful drug for our patients! Looking forward to doing this work in 2025!

As we come to the end of pancreatic cancer awareness month, as an oncologist I have never seen so much excitement in drug development in this setting. From personalised vaccines to off the shelf and kras inhibitors, PRMT5 inhibitors, CD40 agonists and CD73 inhibitors to name a few.